To develop a
radiopharmaceutical for the palliation of painful bone
metastases based on the concept of bifunctional
radiopharmaceuticals, we synthesized a
bisphosphonate derivative labeled with
rhenium-186 (186Re) that contains a
hydroxyl group at the central
carbon of its
bisphosphonate structure, we attached a stable 186Re-MAMA chelate to the amino group of a 4-amino butylidene-
bisphosphonate derivative [N-[2-[[4-[(4-hydroxy-4,4-diphosphonobutyl)amino]-4-oxobutyl]-2-thioethylamino]acetyl]-2-aminoethanethiolate]
oxorhenium (V) (186Re-MAMA-HBP) and we investigated the effect of a
hydroxyl group at the central
carbon of its
bisphosphonate structure on affinity for
hydroxyapatite and on biodistribution by conducting a comparative study with [N-[2-[[3-(3,3-diphosphonopropylcarbamoyl)propyl]-2-thioethylamino]acetyl]-2-aminoethanethiolate]
oxorhenium (V) (186Re-MAMA-BP). The precursor of
186Re-MAMA-HBP, trityl (Tr)-MAMA-HBP, was obtained by coupling a Tr-MAMA derivative to 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
186Re-MAMA-HBP was prepared by a reaction with 186ReO(4-) and SnCl2 in
citrate buffer after the deprotection of the Tr groups of Tr-MAMA-HBP. After reversed-phase high-performance liquid chromatography,
186Re-MAMA-HBP had a radiochemical purity of over 95%. Compared with
186Re-MAMA-BP,
186Re-MAMA-HBP showed a greater affinity for
hydroxyapatite beads in vitro and accumulated a significantly higher level in the femur in vivo. Thus, the introduction of a
hydroxyl group into 186Re complex-conjugated
bisphosphonates would be effective in enhancing accumulation in bones. These findings provide useful information on the design of bone-seeking therapeutic
radiopharmaceuticals.